Alnylam Puts Up $65M To End Tekmira Trade Secrets Battle

Law360, New York (November 13, 2012, 6:55 PM EST) -- Alnylam Pharmaceuticals Inc. has agreed to pay $65 million to Tekmira Pharmaceuticals Corp. as part of a licensing agreement settling a lawsuit that accused it of misappropriating Tekmira's trade secrets related to gene-silencing therapeutics, the companies announced Monday.

The Cambridge, Mass.-based Alnylam agreed to make the payment to Tekmira within 10 days, a sum comprised of $35 million to terminate previous licensing agreements between the two companies and $30 million to secure rights for Alnylam to produce its own lipid nanoparticle technology, or LNP, products in...
To view the full article, register now.